来氟米特治疗免疫球蛋白A肾病的随机对照试验。
Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy.
作者信息
Lou Tanqi, Wang Cheng, Chen Zhujiang, Shi Chenggang, Tang Hua, Liu Xun, Yin Peida, Yu Xueqing
机构信息
Department of Nephrology, Third Affiliated Hospital, Sun Yat-sen University of Medical Science, Guangzhou, China.
出版信息
Nephrology (Carlton). 2006 Apr;11(2):113-6. doi: 10.1111/j.1440-1797.2006.00547.x.
AIM
To investigate the effect of leflunomide for treatment of immunoglobulin A (IgA) nephropathy.
METHODS
Sixty IgA nephropathy patients were divided into two groups at random. Patients in the test group received leflunomide and patients in the control group received fosinopril. Clinical data were obtained at weeks 2, 4, 6, 8, 12, 16, 20, 24 and 28.
RESULTS
The complete remission rate was 62.1% and the total effectiveness rate was 72.4%. In the leflunomide group, proteinuria significantly decreased from 1.66 +/- 0.42 g to 0.60 +/- 0.68 g (P < 0.05). The efficacy rate of leflunomide compared with fosinopril in treating IgA nephropathy was not statistically different (P > 0.05). Side-effects were mild in both treatment groups.
CONCLUSION
These preliminary results are encouraging, but further randomised studies are required before leflunomide can be recommended for the treatment of IgA nephropathy.
目的
探讨来氟米特治疗免疫球蛋白A（IgA）肾病的效果。
方法
将60例IgA肾病患者随机分为两组。试验组患者接受来氟米特治疗，对照组患者接受福辛普利治疗。在第2、4、6、8、12、16、20、24和28周获取临床数据。
结果
完全缓解率为62.1%，总有效率为72.4%。来氟米特组蛋白尿从1.66±0.42g显著降至0.60±0.68g（P<0.05）。来氟米特与福辛普利治疗IgA肾病的有效率无统计学差异（P>0.05）。两个治疗组的副作用均较轻。
结论
这些初步结果令人鼓舞，但在推荐来氟米特用于治疗IgA肾病之前，还需要进一步的随机研究。
Zotero 插件